BeyondSpring to Announce Fourth Quarter and Year End 2020 Financial Results and Host a Conference Call on Friday, April 30, 2021
BeyondSpring Inc. (NASDAQ: BYSI) will report its financial results for the year and quarter ending December 31, 2020, on April 30, 2021. A conference call is scheduled for 8:30 AM ET on the same day to discuss these results and provide a corporate update. BeyondSpring focuses on developing innovative cancer therapies, with its lead asset, plinabulin, aimed at preventing chemotherapy-induced neutropenia and currently under NDA review in the US and China. The company also has a pivotal study in non-small cell lung cancer and various immuno-oncology assets in its pipeline.
- Advanced development of plinabulin, a first-in-class asset under NDA review in US and China.
- Pivotal study fully enrolled for plinabulin targeting non-small cell lung cancer.
- Collaboration with Eli Lilly via subsidiary SEED Therapeutics to enhance drug discovery.
- None.
NEW YORK, April 27, 2021 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced that it will report its financial results for the quarter and year ended December 31, 2020 on Friday, April 30, 2021. Management will also host a conference call with investors to discuss financial results and provide a corporate update at 8:30am Eastern Time.
Conference Call & Webcast Details:
| Date: | Friday, April 30 | |
| Time: | 8:30 am Eastern Time | |
| Toll Free: | 855-327-6837 | |
| International: | 631-891-4304 | |
| Conference ID: | 10014535 | |
| Webcast: | http://public.viavid.com/index.php?id=144757 |
About BeyondSpring
Headquartered in New York City, BeyondSpring is a global biopharmaceutical company focused on developing innovative immuno-oncology cancer therapies to improve clinical outcomes for patients who have high unmet medical needs. BeyondSpring’s first-in-class lead asset plinabulin, a Selective Immunomodulating Microtubule Binding Agent (SIMBA), is a “pipeline in a drug.” It has filed for NDA approval in the US and China for the prevention of chemotherapy-induced neutropenia (CIN) and has a fully enrolled pivotal study to test the anti-cancer benefit, with an overall survival primary endpoint, in non-small cell lung cancer (NSCLC). Additionally, it is being broadly studied in combination with various immuno-oncology agents that could boost the effects of PD-1 / PD-L1 antibodies. In addition to plinabulin, BeyondSpring’s extensive pipeline includes three pre-clinical immuno-oncology assets and a subsidiary, SEED Therapeutics, which is leveraging a proprietary targeted protein degradation (TPD) drug discovery platform, which recently announced an R&D collaboration with Eli Lilly.
Investor Contact:
Ashley R. Robinson
LifeSci Advisors, LLC
+1 617-430-7577
arr@lifesciadvisors.com
Media Contact:
Darren Opland, Ph.D.
LifeSci Communications
+1 646-627-8387
darren@lifescicomms.com
FAQ
When will BeyondSpring release its financial results for 2020?
What time is BeyondSpring's conference call?
What is the ticker symbol for BeyondSpring?
What is plinabulin and its significance for BeyondSpring?
What are the key projects in BeyondSpring's pipeline?
